Clinical Trial Update: Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II clinical trial evaluating a multi-agent immunotherapy regimen (SX-682, TriAdeno Vaccine, Retifanlimab, and IL-15 agonist N-803) for metastatic colo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• N-803
• Retifanlimab (retifanlimab)
• SX-682
• TriAdeno Vaccine

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Colorectal Cancer | Phase 1, Phase 2 | Status: RECRUITING